
New 12-month phase 1/2 data show the BIM-IOL System lowered IOP and kept most patients drop-free after cataract surgery.

New 12-month phase 1/2 data show the BIM-IOL System lowered IOP and kept most patients drop-free after cataract surgery.

In the pivotal BRUNELLO trial, both doses of remigromig, a Wnt pathway agonist, were noninferior to ranibizumab for diabetic macular edema at 1 year.

Access to emergency eye care remains a public health challenge, with gaps that affect patients and communities across the country.

Cost, staffing, unbiased training data, and strong referral partnerships will decide whether AI eye screening reaches patients at highest risk of vision loss.

The director of the National Eye Institute discusses recent advances, AI, and evolving standards of care in ophthalmology.

Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.

Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.

A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

Moderate coffee intake may lower cardiovascular risk, but energy drinks may harm the heart.

The approval is based on findings from the phase 3 SCOUT-HCM trial.

Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.

Pharmacy leaders examined AI for authorizations, adherence, patient access, and efficient specialty pharmacy benefits in health-system care.

The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.

Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.

Chester Good, MD, MPH, shares data and strategies used by UPMC to evaluate value-based contracting in specialty pharmacy.

Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.

Sophy Levine, PharmD, discusses how an integrated health system specialty pharmacy may help lower 1-year GLP-1 discontinuation.

Adaolisa Anaka, PharmD, BCACP, AAHIVP, discusses a pharmacist-led model that targets access barriers to GLP-1 obesity therapy.

Irfana Lakada, PharmD, CSP, explains why onboarding may be the wrong time to screen for social needs and why rescreening matters.

Jesse Dresser explains how federal PBM reform, a new CMS RFI, and FTC settlements could reshape specialty pharmacy contracts and pay from 2027.

HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.

Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.

Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.

A 20-year Danish registry study found higher antidepressant and anxiolytic use among women with endometriosis, both before and after diagnosis.

Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.

Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.

Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.

Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.